Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: ANIK stock price vs ACA: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ACA's multiple
Needs ACA P/S.
Implied fair value · at ANIK's multiple
Needs ANIK P/S.
Metric by metric
Live quote
Price unavailable
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: ANIK FY 2025 (ended Dec 31, 2025) · ACA FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
Anika Therapeutics, Inc. · implied price per share
Bear
-$0.46
Base
-$0.55
Bull
-$0.63
Arcosa, Inc. · implied price per share
Bear
$20.40
Base
$24.00
Bull
$27.60
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.07x
0.58x
Net debt / EBITDA
Leverage against operating earnings
30.49x
3.28x
Cash and equivalents
Liquid reserves on the balance sheet
$81.17M
$214.60M
Total debt
Interest-bearing obligations outstanding
$9.60M
$1.52B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe ANIK can reverse revenue declines and convert its high gross margin into positive operating leverage, then hold or selectively accumulate because the stock is already priced near its P/S-derived fair value; otherwise, the weak growth, negative margins, and high net debt/EBITDA argue against paying up.
ANIK’s current price of $20.73 is almost identical to its implied P/S value of $20.83, suggesting the market is already pricing in the relative valuation framework. The broader range also shows limited upside near the top of ACA-implied band, while the historical trading band places ANIK close to the middle-upper end of its recent range.
Supporting Metrics
